Target Identified To Help Protect Kidney Patients' Heart Health

FG_AUTHORS: Medical News Today

Main Category: Heart Disease
Also Included In: Urology / Nephrology
Article Date: 18 Dec 2012 - 0:00 PST

Current ratings for:
Target Identified To Help Protect Kidney Patients' Heart Health

Healthcare Prof:Target Identified To Help Protect Kidney Patients' Heart Health

Blocking the endothelin receptor reduces risk factors for heart disease, the most common cause of death in kidney disease patients


  • Blocking the receptor for endothelin lowers novel cardiovascular risk factors in patients with chronic kidney disease independent of blood pressure.
  • The findings suggest that blocking the receptor may provide heart-related benefits to these patients.
  • 60 million people globally have chronic kidney disease.
Blocking the receptor for proteins that constrict blood vessels reduces markers of heart-related problems in patients with chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings might be used to improve the health of patients with CKD, who most often die from cardiovascular disease.

Patients with CKD have an increased risk of developing heart problems, in part because kidney disease can cause their arteries to stiffen. This is thought to occur due to an impaired availability of a vasodilator - nitric oxide (NO) - in the blood. The protein endothelin-1 is a vasoconstrictor and opposes the actions of NO, suggesting that drugs that block its effects may help protect CKD patients' heart health. One such drug is called sitaxentan, which blocks endothelin-1's receptor (called the ETA receptor).

Neeraj Dhaun, MD, PhD (University of Edinburgh, in Scotland) and his colleagues conducted a randomized, double-blind study in 27 patients with CKD to compare the effects of sitaxentan, nifedipine (a blood vessel relaxant), and placebo on kidney function, blood pressure, arterial stiffness, and various heart-related markers.

Among the major findings after six weeks of treatment:

  • Placebo and nifedipine did not affect three markers of heart-related problems: blood levels of uric acid; blood levels of asymmetric dimethylarginine (ADMA), a blocker of NO production; and urine levels of endothelin-1.
  • Sitaxentan treatment led to statistically significant reductions in all three of these markers.
  • Sitaxentan reduced proteinuria (an excess excretion of protein in the urine) to a significantly greater extent than nifedipine. Proteinuria is an indicator of kidney dysfunction.
  • Nifedpine and sitaxentan both reduced blood pressure to a similar extent.
"The current study shows, for the first time, that ETA receptor antagonism selectively lowers novel cardiovascular risk factors in patients with kidney disease independent of blood pressure. These effects were seen in patients already receiving optimal treatment," said Dr. Dhaun. "These findings suggest a potential role for ETA receptor antagonism in conferring additional longer-term cardiovascular and renal benefits in patients with kidney disease," he added. Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our
heart disease section for the latest news on this subject.

Study co-authors include: Vanessa Melville, RN, Scott Blackwell, MD, Dinesh Talwar, PhD, Neil Johnston, MSc, Jane Goddard, MD, PhD, and David Webb, MD, FRCP.

Disclosures: This study was funded by Encysive Pharmaceuticals and Pfizer. Drs. Dhaun, Goddard, and Webb have all received research grants from Pfizer. Drs. Dhaun and Goddard have held academic research fellowships funded by educational grants from Pfizer. Drs. Goddard and Webb have acted as Consultants to Pfizer.

Sitaxentan has been voluntarily withdrawn by Pfizer, Ltd due to unacceptable side effects. However, the findings of this study are likely to be representative of the effects of the class of selective endothelin A receptor antagonists.

The article, entitled "Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD," will appear online on at December 13, 2012, doi: 10.1681/2012040355.

American Society of Nephrology

Please use one of the following formats to cite this article in your essay, paper or report:


n.p. "Target Identified To Help Protect Kidney Patients' Heart Health." Medical News Today. MediLexicon, Intl., 18 Dec. 2012. Web.
18 Dec. 2012. <>


Please note: If no author information is provided, the source is cited instead.

'Target Identified To Help Protect Kidney Patients' Heart Health'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Read more

PUA Social Network

Twitter Facebook

Contact us

The Philippine Urological Association,Inc
3rd floor. PCS Bldg., 992 EDSA, Quezon City,
Metro Manila, PHILIPPINES 1105
View Map


eMail us